Biosimilars in the Treatment of Inflammatory Bowel Disease

Abstract Purpose of Review Biosimilars are antibody-based therapies that are highly similar to originator biologic molecules. The unique, streamlined authorization process for biosimilars has resulted in the approval and relatively rapid availability of numerous biosimilar agents for the treatment of Crohn’s disease and ulcerative colitis. In this narrative review, we provide a detailed overview of the evidence, evaluating the efficacy and safety of biosimilars in the management of inflammatory bowel disease. Recent Findings Multiple clinical trials have examined the use of infliximab biosimilars in the treatment of inflammatory bowel disease, including PROSIT-BIO, PLANET-CD, and NOR-SWITCH, collectively demonstrating similar effectiveness and safety outcomes between infliximab biosimilars and originator infliximab. Data from VOLTAIRE-CD evaluated an adalimumab biosimilar in the treatment of Crohn’s disease and found no significant difference in efficacy or safety compared to the reference biologic. Ustekinumab biosimilar clinical trial data is primarily limited to the plaque psoriasis patient population, with multiple studies demonstrating no major differences between biosimilar and originator in key clinical endpoints. Summary The available evidence supports the use of biosimilars as effective and safe alternatives to originator therapies. While clinical trials have examined infliximab and adalimumab biosimilars in patients with inflammatory bowel disease, there is a paucity of clinical trials evaluating ustekinumab in the Crohn’s disease and ulcerative colitis populations, instead relying on extrapolation in other inflammatory conditions.

Authors

Institutions

Publication Details

Journal
Current Treatment Options in Gastroenterology
Published
2026-11-17
DOI
https://doi.org/10.1007/s11938-026-00502-1
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biosimilars in the Treatment of Inflammatory Bowel Disease

Gary R. Lichtenstein, Andrew T. Weber
Current Treatment Options in Gastroenterology
Biosimilars and Bioanalytical Methods
article

Biosimilars in the Treatment of Inflammatory Bowel Disease

Gary R. Lichtenstein, Andrew T. Weber
article en

Abstract

Abstract Purpose of Review Biosimilars are antibody-based therapies that are highly similar to originator biologic molecules. The unique, streamlined authorization process for biosimilars has resulted in the approval and relatively rapid availability of numerous biosimilar agents for the treatment of Crohn’s disease and ulcerative colitis. In this narrative review, we provide a detailed overview of the evidence, evaluating the efficacy and safety of biosimilars in the management of inflammatory bowel disease. Recent Findings Multiple clinical trials have examined the use of infliximab biosimilars in the treatment of inflammatory bowel disease, including PROSIT-BIO, PLANET-CD, and NOR-SWITCH, collectively demonstrating similar effectiveness and safety outcomes between infliximab biosimilars and originator infliximab. Data from VOLTAIRE-CD evaluated an adalimumab biosimilar in the treatment of Crohn’s disease and found no significant difference in efficacy or safety compared to the reference biologic. Ustekinumab biosimilar clinical trial data is primarily limited to the plaque psoriasis patient population, with multiple studies demonstrating no major differences between biosimilar and originator in key clinical endpoints. Summary The available evidence supports the use of biosimilars as effective and safe alternatives to originator therapies. While clinical trials have examined infliximab and adalimumab biosimilars in patients with inflammatory bowel disease, there is a paucity of clinical trials evaluating ustekinumab in the Crohn’s disease and ulcerative colitis populations, instead relying on extrapolation in other inflammatory conditions.

Current Treatment Options in GastroenterologyVol. 24(1)
University of Pennsylvania (US)
Good health and well-being
Biosimilars and Bioanalytical Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon